[
    [
        {
            "time": "2018-01-02",
            "original_text": "Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales",
            "features": {
                "keywords": [
                    "RDUS",
                    "Narrower",
                    "Q4",
                    "Loss",
                    "Robust",
                    "Tymlos",
                    "Sales"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "5 Pharmaceutical Stocks With Big Moats and Bridges",
            "features": {
                "keywords": [
                    "Pharmaceutical",
                    "Stocks",
                    "Big",
                    "Moats",
                    "Bridges"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "5 Pharmaceutical Stocks With Big Moats and Bridges",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "3 Big Stock Charts for Friday: Eli Lilly, Centene and LKQ Corporation",
            "features": {
                "keywords": [
                    "Big",
                    "Stock",
                    "Charts",
                    "Eli",
                    "Lilly",
                    "Centene",
                    "LKQ",
                    "Corporation"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "automotive"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Big Stock Charts for Friday: Eli Lilly, Centene and LKQ Corporation",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "MTUM, JNJ, LLY, KO: ETF Inflow Alert",
            "features": {
                "keywords": [
                    "MTUM",
                    "JNJ",
                    "LLY",
                    "KO",
                    "ETF",
                    "Inflow",
                    "Alert"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "MTUM, JNJ, LLY, KO: ETF Inflow Alert",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Eli",
                    "Lilly",
                    "Tax",
                    "Debt"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Nektar Therapeutics (NKTR) Q4 2018 Earnings Conference Call Transcript",
            "features": {
                "keywords": [
                    "Nektar",
                    "Therapeutics",
                    "NKTR",
                    "Q4",
                    "2018",
                    "Earnings",
                    "Conference",
                    "Call",
                    "Transcript"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Nektar Therapeutics (NKTR) Q4 2018 Earnings Conference Call Transcript",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Comparing AstraZeneca’s and Eli Lilly’s Dividends",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Eli",
                    "Lilly",
                    "Dividends"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Comparing AstraZeneca’s and Eli Lilly’s Dividends",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",
            "features": {
                "keywords": [
                    "Daily",
                    "Biotech",
                    "Pulse",
                    "Puma",
                    "Biotech",
                    "Earnings",
                    "Mersana",
                    "Offering",
                    "Orphan",
                    "Drug",
                    "Designation",
                    "Ascendis"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Eli",
                    "Lilly",
                    "Controlling",
                    "Expenses",
                    "Better"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting",
            "features": {
                "keywords": [
                    "Lilly",
                    "Present",
                    "Data",
                    "Demonstrating",
                    "Continued",
                    "Scientific",
                    "Advancements",
                    "Broad",
                    "Dermatology",
                    "Portfolio",
                    "AAD",
                    "Annual",
                    "Meeting"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]